Expert Cv Joint

[Chieko Boteler]

TheJoint FAO/WHO Expert Committee on Food Additives (JECFA) is an international scientificexpert committee that is administered jointly by the Food and Agriculture Organization of theUnited Nations (FAO) and the World Health Organization (WHO). It has been meeting since 1956,initially to evaluate the safety of food additives. Its work now also includes the evaluation ofcontaminants, naturally occurring toxicants and residues of veterinary drugs in food.

To date, JECFA has evaluated more than 2600 food additives, approximately 50 contaminants andnaturally occurring toxicants, and residues of approximately 75 veterinary drugs. The Committeealso develops principles for the safety assessment of chemicals in food that are consistent withcurrent thinking on risk assessment and take account of recent developments in toxicology and otherrelevant scientific areas such as epidemiology, biotechnology, exposure assessment, food chemistryincluding analytical chemistry and assessment of maximum residue limits for veterinary drugs.

JECFA normally meets twice a year with individual agendas covering either (i) food additives,contaminants and naturally occurring toxicants in food or (ii) residues of veterinary drugs in food.The membership of the meetings varies accordingly, with different sets of experts being called ondepending on the subject matter.

JECFA serves as an independent scientific expert committee which performs risk assessments andprovides advice to FAO, WHO and the member countries of both organizations, as well as to theCodex Alimentarius Commission (CAC). The requests for scientific advice are for the main partchannelled through the subsidiary bodies of the CAC in their work to develop international foodstandards and guidelines under the Joint FAO/WHO Food Standards Programme. The advice toCAC on food additives, contaminants and naturally occurring toxicants is normally provided to theCodex Committee on Food Additives (CCFA) and to the Codex Committee on Contaminants infood (CCCF), and advice on residues of veterinary drugs to the Codex Committee on Residues ofVeterinary Drugs in Food (CCRVDF).

All countries need to have access to reliable risk assessment of chemicals in food, but not all havethe expertise and funds available to carry out separate risk assessments on large numbers ofchemicals. JECFA performs a vital role in providing a reliable and independent source of expertadvice in the international setting, thus contributing to the setting of standards on a global scale forthe health protection of all consumers and for ensuring fair practices in the trade of safe food. Somecountries use information from JECFA in the establishment of national food safety controlprogrammes and CCFA, CCCF and CCRVDF develop standards based on evaluations by JECFA.

A particularly important aspect of the work of Codex Committees results from the agreement, as aresult of the Uruguay Round in which the World Trade Organization (WTO) succeeded the GeneralAgreement on Tariffs and Trade, that scientific, risk-based standards established by the CodexAlimentarius Commission should be employed under terms of the Sanitary and Phytosanitary (SPS)agreement to address fair trade practices. Governments wishing to argue particular cases at WTOare likely, therefore, to turn increasingly to Codex, and through Codex to JECFA and otherscientific bodies, for advice on their own legislation.

There are no preventive screenings for hips or knees, so pain is a major tip-off that trouble may be brewing. Some people don't even realize they have hip or knee issues until they experience pain doing new activities or movements.

Over the years, innovations in hip and knee implants and surgical techniques have made the operations even more technically precise, Dr. Sierra says. New plastics used in hip and knee replacements are extremely durable.

Changes in anesthesia and pain control techniques have improved the care given to patients before, during and after surgery. More people are having outpatient hip and knee replacement surgery. If you do get a knee or hip replacement, your doctor will likely recommend being conservative with your activities.

Looking ahead, Dr. Sierra says avascular necrosis, or the death of bone tissue, remains one of the unsolved issues in hip surgery, with much research still ahead. Also, research continues into abductor tears or tears of the muscles around the hip. Women are especially prone to this condition.

About Mayo Clinic

Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news.

Officially known as Quality Assurance Specialist (Ammunition Surveillance), about a dozen JMC QASAS personnel recently deployed to Europe from various Army depots and ammunition plants across the U.S. These ammunition experts now fall under the command and control of the 405th Army Field Support Brigade.

Positioned at multiple locations in Germany as well as forward locations like Poland, QASAS personnel are responsible for providing expert technical ammunition and explosives assistance and support to units stationed in or deployed to Europe.

Paul Leykamm is one of the QASAS personnel deployed to Poland. Leykamm, who has 17 years of experience as a QASAS and is home-stationed at Rock Island Arsenal, Illinois, has been on ground in Zagan, Poland, providing Class 5 ammunition and explosives technical assistance to deployed and rotational units there for the past two months.

Additionally, several more QASAS personnel are deployed to Germany supporting ammunition operations at the Ammunition Center Europe, or ACE, in Miesau as well as operations in Ansbach and Wiesbaden. Aaron Thornton, who also has 17 years as a QASAS, is one of them.

Thornton is a supervisor at ACE. Home-stationed at Tooele Army Depot, Utah, he arrived to Germany about a month ago. He manages a team at Miesau where all ammunition and explosives that transit to and from the center are thoroughly inspected, including missiles.

Thornton said he has Soldiers working with his team at the ACE from the 8th Ordnance Company who are deployed to Europe from Fort Bragg, North Carolina. According to Thornton, deploying overseas has provided these Soldiers with additional opportunities.

Doss, who has been a QASAS for about two years, normally works at Crane Army Ammunition Activity located in Indiana. He said the QASAS team at the ACE is currently inspecting a large shipment of ammunition that arrived at Miesau a few days ago, and so far everything looks good.

There has been a significant increase in the use of short-term percutaneous ventricular assist devices (pVADs) as acute circulatory support in cardiogenic shock and to provide haemodynamic support during interventional procedures, including high-risk percutaneous coronary interventions. Although frequently considered together, pVADs differ in their haemodynamic effects, management, indications, insertion techniques, and monitoring requirements. This consensus document summarizes the views of an expert panel by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the Association for Acute Cardiovascular Care (ACVC) and appraises the value of short-term pVAD. It reviews the pathophysiological context and possible indications for pVAD in different clinical settings and provides guidance regarding the management of pVAD based on existing evidence and best current practice.

This consensus document summarizes the views of an expert panel endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the Association for Acute Cardiovascular Care (ACVC) and appraises the importance of short-term percutaneous ventricular assist device (pVAD). It reviews the pathophysiological context, initiation, and indications for pVAD in different clinical settings and provides guidance regarding the management of pVAD based on existing evidence and best current practice.

There has been a significant increase in the implementation of short-term percutaneous ventricular assist device (pVAD) in recent years, aiming to improve outcomes in cardiogenic shock (CS) and high-risk percutaneous coronary intervention (HR-PCI). These devices aim to reduce cardiac stroke work and myocardial oxygen demand whilst maintaining systemic and coronary perfusion.1,2 Although frequently considered interchangeable, the indications, management and evidence supporting the use of various types of pVAD differ significantly.3 This Joint European Association of Percutaneous Cardiovascular Interventions (EAPCI)/Association for Acute Cardiovascular Care (ACVC) expert consensus document reviews the pathophysiological context and indications for pVAD in different clinical settings and provides guidance regarding the clinical management of patients requiring pVAD.

The rationale and indications (Table 2) for pVAD in high-risk percutaneous coronary intervention (PCI) are described in the Supplementary material online. The aims of pVAD in the setting of HR-PCI are to initiate haemodynamic support in very high-risk patients before the intervention, to prevent profound hypotension/low cardiac output (CO) episodes, and allow sufficient time to achieve optimal and complete revascularization (Table 2).1,16

The rationale and indications (Table 3) for pVAD in high-risk acute myocardial infarction (AMI) without CS are described in the Supplementary material online. In high-risk AMI, unloading of the left ventricle can be initiated prior to reperfusion in order to rapidly reduce wall tension and potentially reduce myocardial damage.19,20 No data from randomized trials or long-term outcomes of a pre-emptive unloading strategy are available, however, the DTU (Door to Unload) trial is currently enrolling patients (Table 3).

The rationale and indications (Table 4) for pVAD in CS are described in the Supplementary material online. Left-sided pVADs primarily aim to restore CO in patients with CS or in case of refractory cardiac arrest. There are, however, no randomized clinical trials addressing optimal timing or selection of pVAD in CS. Outside the cardiac arrest setting, usual practice is to initiate pVAD in CS as soon as possible, and before the onset of multi-organ failure. In patients with CS complicating AMI, registry data (uncontrolled and with inherent selection bias) suggest higher survival rates with device placement before revascularization than after in patients with AMI and CS.27 These findings have been supported by preclinical data.20 Recent data in a larger cohort of CS patients have challenged the concept of pre-emptive device placement.34 Until high-quality data are available, decisions regarding the timing of pVAD initiation (as with every pMCS), are therefore based on the risk/benefit assessment, including severity of shock and the burden of comorbidity, as evaluated by the multidisciplinary shock team.

3a8082e126